Patents Represented by Attorney J. Scott Young

Find this attorney in the Justia Lawyer Directory

  • Chemical compounds
    Patent number: 7648990
    Abstract: The present invention provides a method for the treatment of emesis in a mammal being treated with an opiod analgesic.
    Type: Grant
    Filed: October 1, 2007
    Date of Patent: January 19, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Giuseppe Alvaro, Paola Maragni, Marsia Tampieri
  • Pyrimidine derivatives and their use as CB2 modulators
    Patent number: 7635701
    Abstract: The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.
    Type: Grant
    Filed: August 19, 2003
    Date of Patent: December 22, 2009
    Assignee: Glaxo Group Limited
    Inventors: Andrew John Eatherton, Gerard Martin Paul Giblin, Richard Howard Green, Jennifer Margaret Doughty, legal representative, William Leonard Mitchell, Alan Naylor, Derek Anthony Rawlings, Brian Peter Slingsby, Andrew Richard Whittington
  • Pyrrolopyridine derivatives
    Patent number: 7589206
    Abstract: The present invention relates to novel pyrrolopyridine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.
    Type: Grant
    Filed: June 7, 2005
    Date of Patent: September 15, 2009
    Assignee: Glaxo Group Limited
    Inventors: Andrew John Eatherton, Gerard Martin Paul Giblin, Matthew Russell Johnson, William Leonard Mitchell, Brian Peter Slingsby, Alcide Perboni
  • Quinoline derivatives as phosphodiesterase inhibitors
    Patent number: 7572915
    Abstract: There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20, and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
    Type: Grant
    Filed: February 8, 2006
    Date of Patent: August 11, 2009
    Assignee: Glaxo Group Limited
    Inventors: Michael David Barker, Anthony William Dean, Brian Evans, Stuart Holman, Michael Woodrow
  • Cycloalkylidene compounds as modulators of estrogen receptor
    Patent number: 7569601
    Abstract: The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation.
    Type: Grant
    Filed: May 14, 2007
    Date of Patent: August 4, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Jing Fang, Dennis Heyer, Aaron Bayne Miller, Frank Navas, III, Terrence Lee Smalley, Jr., William J. Zuercher, Subba Reddy Katamreddy
  • Quinoline derivatives as phosphodiesterase inhibitors
    Patent number: 7566786
    Abstract: There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20, and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: July 28, 2009
    Assignee: Glaxo Group Limited
    Inventors: Ian Robert Baldwin, Michael David Barker, Anthony William Dean, Colin David Eldred, Brian Evans, Sharon Lisa Gough, Stephen Barry Guntrip, Julie Nicole Hamblin, Stuart Holman, Paul Jones, Mika Kristian Lindvall, Christopher James Lunniss, Tracy Jane Redfern, Alison Judith Redgrave, John Edward Robinson, Michael Woodrow
  • Cycloalkylidene compounds as modulators of estrogen receptor
    Patent number: 7560589
    Abstract: The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation.
    Type: Grant
    Filed: July 27, 2004
    Date of Patent: July 14, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Jonathan E. Britton, Jing Fang, Dennis Heyer, Aaron Bayne Miller, Frank Navas, III, Terrence Lee Smalley, Jr., William J. Zuercher, Subba Reddy Katamreddy
  • 1,2-Diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
    Patent number: 7550498
    Abstract: The present invention relates to derivatives of 1,2-diaza-dibenzoazulene, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory actions, especially to the inhibition of tumor necrosis factor-? (TNF-?) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: June 23, 2009
    Assignee: GlaxoSmithKline Istrazivacki Centar Zagreb d.o.o.
    Inventors: Mladen Mercep, Milan Mesic, Dijana Pesic
  • Purine derivatives as liver X receptor agonists
    Patent number: 7495004
    Abstract: The invention relates to methods for the treatment or prevention of an LXR mediated disease or condition, including cardiovascular disease and atherosclerosis, novel compounds of formula (I) for use in such methods and pharmaceutical compositions comprising compounds for use in such methods.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: February 24, 2009
    Assignee: Glaxo Group Limited
    Inventors: Sharon Davis Boggs, Jon Loren Collins, Adam Fivush, Eugene Lee Stewart, Timothy Mark Willson
  • Cox-2 inhibiting pyridine derivatives
    Patent number: 7446117
    Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever and inflammation of a variety of conditions and diseases.
    Type: Grant
    Filed: September 12, 2003
    Date of Patent: November 4, 2008
    Assignee: Glaxo Group Limited
    Inventors: Paul Beswick, Neil Pegg, Martin Swarbrick, John Skidmore, Sandeep Modi
  • Triphenylethylene compounds as selective estrogen receptor modulators
    Patent number: 7442833
    Abstract: Compounds of formula (I): with a variety of therapeutic uses, more particularly novel prodrugs that are particularly useful for delivering a parent compound for selective estrogen receptor modulation.
    Type: Grant
    Filed: October 4, 2004
    Date of Patent: October 28, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: John Fred Eaddy, III, Dennis Heyer, Amarjit Sab Randhawa, Vicente Samano, John Albert Ray, Subba Reddy Katamreddy, Michael Tolar Martin, Michael Scott McClure
  • 2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
    Patent number: 7435834
    Abstract: The present invention relates to compounds of 2-thia-dibenzoazulene class, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumour necrosis factor-?(TNF-?) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.
    Type: Grant
    Filed: April 9, 2003
    Date of Patent: October 14, 2008
    Assignee: GlaxoSmithKline Istrazivacki Center Zagreb D.O.O.
    Inventors: Mladen Mercep, Milan Mesic, Dijana Pesic, Ivana Ozimec
  • Substituted quinoline compounds for use as selective estrogen receptor modulator
    Patent number: 7405303
    Abstract: The present invention relates to novel compounds of formula (I) with a variety of therapeutic uses, more particularly novel substituted quinoline compounds particularly useful for selective estrogen receptor modulation.
    Type: Grant
    Filed: February 22, 2005
    Date of Patent: July 29, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: William Joel Hoekstra, Aaron Bayne Miller, William John Zuercher, Harikrishna Suryakant Patel
  • 1-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
    Patent number: 7312203
    Abstract: The present invention relates to 1-aza-dibenzoazulene derivatives, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumour necrosis factor-? (TNF-?) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: December 25, 2007
    Assignee: GlaxoSmithKline istraziva{hacek over (c)}ki Centar Zagreb d.o.o.
    Inventors: Mladen Mercep, Milan Mesic, Dijana Pesic
  • 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
    Patent number: 7262309
    Abstract: The present invention relates to benzonaphthoazulene derivatives of tiophene class, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumor necrosis factor-? (TNF-?) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.
    Type: Grant
    Filed: October 12, 2004
    Date of Patent: August 28, 2007
    Assignee: GlaxoSmith Kline Istrazivocki Centar Zagreb, D.O.O.
    Inventors: Mladen Mercep, Milan Mesic, Dijana Pesic, Ivana Ozimec, Rudolf Trojko
  • 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
    Patent number: 7262302
    Abstract: The present invention relates to derivatives of 1-thia-3-aza-dibenzoazulene class, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumour necrosis factor-? (TNF-?) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: August 28, 2007
    Assignee: GlaxoSmithKline Istrazivacki Centar Zagreb, D.O.O.
    Inventors: Mladen Mercep, Milan Mesic, Marina Modric, Dijana Pesic, Davor Kidemet
  • Pyrimidine derivative as selective COX-2 inhibitors
    Patent number: 7235560
    Abstract: The invention provides the compounds of formula (I) or a pharmaceutically acceptable salt thereof. Compounds of formula (I) are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever and inflammation of a variety of conditions and diseases.
    Type: Grant
    Filed: August 15, 2003
    Date of Patent: June 26, 2007
    Assignee: Glaxo Group Limited
    Inventors: Gordon Weingarten, Gianpaolo Bravi
  • (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives
    Patent number: 7232821
    Abstract: Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, R1, R2, Rx, R8, R9 and n are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.
    Type: Grant
    Filed: April 7, 2003
    Date of Patent: June 19, 2007
    Assignee: Glaxo Group Limited
    Inventors: Gerard Martin Paul Giblin, Adrian Hall, David Nigel Hurst, Ian Reginald Kilford, Xiao Qing Lewell, Alan Naylor, Riccardo Novelli
  • 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof
    Patent number: 7232815
    Abstract: The present invention relates to derivatives of 1-oxa-3-aza-dibenzoazulene class, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory actions, especially to the inhibition of tumour necrosis factor-? (TNF-?) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.
    Type: Grant
    Filed: April 9, 2003
    Date of Patent: June 19, 2007
    Assignee: GlaxoSmithKline
    Inventors: Mladen Mercep, Milan Mesic, Dijana Pesic, Iva Benko
  • Pyrazolopyridine derivatives as selective cox-2 inhibitors
    Patent number: 7223772
    Abstract: The invention provides the compounds of formula (I) and pharmaceutically acceptable derivatives thereof wherein: R0 and R1 are independently selected from the group consisting of H, halogen, C1-6alkyl, C1-6alkoxy, and C1-6alkoxy substituted by one or more fluorine atoms; R2 is selected from the group consisting of H, C1-6alkyl, C1-6alkyl substituted by one or more fluorine atoms, C1-6alkoxy, C1-6hydroxyalkyl, SC1-6alkyl, C(O)H, C(O)C1-6alkyl, C1-6alkylsulphonyl, and C1-6alkoxy substituted by one or more fluorine atoms; and R3 is C1-6alkyl or NH2. Compounds of formula (I) are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever, inflammation of a variety of conditions and diseases.
    Type: Grant
    Filed: November 1, 1999
    Date of Patent: May 29, 2007
    Assignee: SmithKline Beecham Corporation
    Inventors: Ian Baxter Campbell, Alan Naylor